Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising ovarian cancer drug study pulled before it began

NCT ID NCT06545617

Disease control Sponsor: Bio-Thera Solutions Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test a new drug called BAT8006 in people with ovarian cancer that no longer responds to platinum-based chemotherapy. The drug works by targeting a protein on cancer cells to deliver a toxic payload directly. However, the study was withdrawn before any participants were enrolled, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Started

Jan 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to give voluntary informed consent and understand the study and are willing to follow and complete all the study required procedures. 2. Women ≥ 18 years old. 3. Subjects with histologically or cytologically confirmed platinum-resistant, advanced or metastatic epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. 4. Presence of at least one measurable lesion per RECIST v1.1. that was not in a prior radiation or other locally treated area. 5. Life expectancy ≥ 3 months. 6. Adequate hematological, liver, kidney and coagulation function. Exclusion Criteria 1. Females who are pregnant or nursing. 2. Had major surgery within 28 days of the Screening visit. 3. History of autologous transplantation ≤ 3 months 4. History of severe infection deemed clinically significant by the PI or designee within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose of study drug. 5. History of human immunodeficiency virus (HIV) infection. 6. Active hepatitis B or C. 7. Any other serious underlying medical. 8. Received cancer-directed therapy within the timeframes. 9. Subjects have other active malignancies within 5 years prior to the first dose. 10. Known allergies, hypersensitivity, or intolerance to the study drug or its excipients. 11. Vaccinated with any live-attenuated vaccine within 4 weeks. 12. Subjects with known history of psychiatric disorders, drug abuse, alcoholism or drug addiction. 13. Subjects who are estimated by the investigator to have poor compliance with the clinical study or who have other factors that are not appropriate to participate in the study in the opinion of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube cancer Platinum-resistant epithelial ovarian cancer Primary peritoneal cancer

More trials for these conditions

Other studies related to the condition(s) this trial covers.